Full Document here:
CONSENSUS STATEMENT
Improving access to care and treatment for Huntington’s Disease patients and families. Sign our petition
Triplet Therapeutics – Developing Treatment for Huntington’s Disease
Triplet Therapeutics is working on somatic instability as a way of possibly treating Huntingon’s Disease (HD)
During this video, we asked Nessan Bermingham, Brian Bettencourt, Irina Antonijevic & Dr. Anne Rosser about Triplet’s mission and their new approach. They also introduced Triplet’s natural history study of Huntington’s disease, called SHIELD HD.
COVID-19 & HUNTINGTON’S DISEASE
Associations
Find Huntington's Disease
Associations near you
Resources
Different resources
developed for you
Ask our Doctor
Do you have any questions?
Ask our doctor
Events
Find out more about
upcoming events
NEWS
About the Phase I/II Clinical Program of AMT-130
This HD clinical trial will explore the safety, tolerability, and efficacy signals in 26 total patients with early manifest HD. “We are very pleased with the progress that we continue to make in this Phase 1-2 clinical trial and that we are now administering AMT-130 at the higher dose,” said Ricardo Dolmetsch, Ph.D., president of research at uniQure.
You are kindly invited to join the 1st Huntington’s Disease Meeting for the Arabic Countries, organised by the International Huntington Association 
. This is the first in a series of educational events dealing with Huntington’s Disease and will take place via Zoom.
Scientists identify precisely how pridopidine works in models of Huntington’s disease.
Pridopidine is a drug developed to treat Huntington’s disease (HD) and now scientists have a clearer understanding of how it works in the body and brain.